Showing results (21-30 of 163) with videos related to

Sort By:
Pageof 17
Oncoscience|January 17, 2015
Non-coding RNAs in lung cancerBiagio Ricciuti, Carmen Mecca, Lucio Crinò, et al.
Oncology and Therapy|July 24, 2020
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature ReviewGiulio Metro, Sara Baglivo, Riccardo Moretti, et al.
Clinical Lung Cancer|June 6, 2020
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint InhibitorsAlex Friedlaender, Stephen V Liu, Antonio Passaro, et al.
Cancer Treatment Reviews|January 30, 2022
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLCAlex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, et al.
Anticancer Research|July 15, 2009
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practiceAlessandra Fabi, Michelangelo Russillo, Giulio Metro, et al.
Future Oncology (London, England)|February 19, 2013
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancerGiulio Metro, Rita Chiari, Alice Baldi, et al.
Drugs in Context|August 1, 2022
Non-small-cell lung cancer: how to manage <i>RET</i>-positive diseaseElisa Andrini, Mirta Mosca, Linda Galvani, et al.
Oncology (Williston Park, N.Y.)|September 1, 2005
Perspectives on salvage therapy for non-small-cell lung cancerFederico Cappuzzo, Giovanna Finocchiaro, Rocco Trisolini, et al.
Clinical Drug Investigation|August 29, 2018
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer PatientGiulio Metro, Sara Baglivo, Annamaria Siggillino, et al.
Oncology and Therapy|July 24, 2020
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the LiteratureSara Baglivo, Vienna Ludovini, Riccardo Moretti, et al.
Pageof 17